Terms: = Endocrine gland cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Treatment
7 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. SOAT1: A Suitable Target for Therapy in High-Grade Astrocytic Glioma?
Löhr M; Härtig W; Schulze A; Kroiß M; Sbiera S; Lapa C; Mages B; Strobel S; Hundt JE; Bohnert S; Kircher S; Janaki-Raman S; Monoranu CM
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409086
[TBL] [Abstract] [Full Text] [Related]
3. Targeting the Stress-Induced Protein NUPR1 to Treat Pancreatic Adenocarcinoma.
Santofimia-Castaño P; Xia Y; Peng L; Velázquez-Campoy A; Abián O; Lan W; Lomberk G; Urrutia R; Rizzuti B; Soubeyran P; Neira JL; Iovanna J
Cells; 2019 Nov; 8(11):. PubMed ID: 31744261
[TBL] [Abstract] [Full Text] [Related]
4. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct idh-Mutant Molecular Profiles.
Farshidfar F; Zheng S; Gingras MC; Newton Y; Shih J; Robertson AG; Hinoue T; Hoadley KA; Gibb EA; Roszik J; Covington KR; Wu CC; Shinbrot E; Stransky N; Hegde A; Yang JD; Reznik E; Sadeghi S; Pedamallu CS; Ojesina AI; Hess JM; Auman JT; Rhie SK; Bowlby R; Borad MJ; ; Zhu AX; Stuart JM; Sander C; Akbani R; Cherniack AD; Deshpande V; Mounajjed T; Foo WC; Torbenson MS; Kleiner DE; Laird PW; Wheeler DA; McRee AJ; Bathe OF; Andersen JB; Bardeesy N; Roberts LR; Kwong LN
Cell Rep; 2017 Mar; 18(11):2780-2794. PubMed ID: 28297679
[TBL] [Abstract] [Full Text] [Related]
5. A high-throughput analysis of the idh1(R132H) protein expression in pituitary adenomas.
Casar-Borota O; Øystese KA; Sundström M; Melchior L; Popovic V
Pituitary; 2016 Aug; 19(4):407-14. PubMed ID: 27097804
[TBL] [Abstract] [Full Text] [Related]
6. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract] [Full Text] [Related]
7. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract] [Full Text] [Related]
